Neose is a clinical-stage biopharmaceutical company focused on the development of next-generation therapeutic proteins that are competitive with best-in-class protein drugs currently on the market. We believe that our enzymatic pegylation technology, GlycoPEGylation™, can improve the drug properties of therapeutic proteins by building out, and attaching polyethylene glycol (PEG) to, carbohydrate structures on the proteins. We are using our technology to develop proprietary versions of protein drugs with proven safety and efficacy and to improve the therapeutic profiles of proteins being developed by our partners. We expect these modified proteins to offer significant advantages, including less frequent dosing and possibly improved efficacy, over the original versions of the drugs now on the market, as well as to meet or exceed the pharmacokinetic profile of next-generation versions of the drugs now on the market. We believe this strategy of targeting drugs with proven safety and efficacy allows us to lower the risk profile of our proprietary development portfolio as compared to de novo protein drug development.
The table below provides an overview of the therapeutic protein candidates currently in our pipeline:
COMPOUND |
INDICATION |
DEVELOPMENT STATUS |
PARTNERSHIP STATUS |
MARKET OPPORTUNITY |
| GlycoPEG-GCSF | Neutropenia | Phase I | Co-development with BioGeneriX AG | $4 B |
| Factor VIIa | Bleeding episodes in patients with inhibitors to Factors VIII or IX | Phase I | License agreement with Novo Nordisk A/S | $1 B |
| Factor VIII | Hemophilia A | Research | License agreement with Novo Nordisk A/S | $2 B |
| Factor IX | Hemophilia B | Research | License agreement with Novo Nordisk A/S | $350 M |
Neose employs approximately
50 people and operates out of its location in Horsham, Pennsylvania. Neose operated
as a private company until 1996 when it became publicly traded on the NASDAQ
under the ticker symbol NTEC.
Print
right half of page content